Stay updated on Aptose Biosciences Press Releases

Sign up to get notified when there's something new on the Aptose Biosciences Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Aptose Biosciences Press Releases page

  1. Check
    6 days ago
    Change Detected
    Summary
    Added a new press release entry dated Dec 06, 2025 announcing Aptose’s Tuspetinib triple-drug therapy featured at the 2025 ASH Annual Meeting. Removed the Aug 01, 2025 notice about selecting Ernst & Young as auditor and the reconvened shareholders meeting.
    Difference
    2%
    Check dated 2025-12-10T03:46:16.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    Added the press release: Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical (Nov 19, 2025). Deleted the July 15, 2025 press release titled Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML.
    Difference
    2%
    Check dated 2025-11-25T22:16:29.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    New entries have been added to the press releases list, including Aptose Reports Third Quarter 2025 Results on Nov 13, 2025. An older release about Aptose Upgraded to Trade on OTCQB Market was removed, updating the current archive.
    Difference
    2%
    Check dated 2025-11-18T20:56:25.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Adds a new press release entry for Nov 3, 2025: 'Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting' and removes the Jun 30, 2025 'Aptose Announces Deferral of Interest Payment' entry along with related header/column labels.
    Difference
    3%
    Check dated 2025-11-04T04:27:08.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    New(s): Positive clinical results for Tuspetinib across diverse AML populations. Removed: Loan agreement news related to Tuspetinib funding. The page now emphasizes efficacy over financing.
    Difference
    17%
    Check dated 2025-10-21T01:19:54.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
     Softer: Replaced a general corporate update with a targeted press release about continuing a loan agreement for a leukemia therapy (Tuspetinib) in triplet therapy with Hanmi, including exact timestamp.
    Difference
    12%
    Check dated 2025-09-29T09:51:10.000Z thumbnail image

Stay in the know with updates to Aptose Biosciences Press Releases

Enter your email address, and we'll notify you when there's something new on the Aptose Biosciences Press Releases page.